![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. (2s)-2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)hexanamide
2. Bal101553
1. Bal101553
2. Bal-101553
3. Lisavanbulin [inn]
4. Lisavanbulin [usan]
5. 1263384-43-5
6. 5pt0qp06x5
7. Microtubule-targeted Agent Bal101553
8. (2s)-2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)hexanamide
9. Hexanamide, 2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)-, (2s)-
10. Lisavanbulin (usan/inn)
11. Lisavanbulin [usan:inn]
12. Unii-5pt0qp06x5
13. Lisavanbulin [who-dd]
14. Schembl1160313
15. Chembl4297595
16. Glxc-25728
17. Ex-a4306
18. Nsc764608
19. Nsc789724
20. Who 10401
21. Bal 101553
22. Db15224
23. Nsc-764608
24. Nsc-789724
25. D11494
26. Q27262705
Molecular Weight | 515.6 g/mol |
---|---|
Molecular Formula | C26H29N9O3 |
XLogP3 | 1.5 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 13 |
Exact Mass | 515.23933582 g/mol |
Monoisotopic Mass | 515.23933582 g/mol |
Topological Polar Surface Area | 191 Ų |
Heavy Atom Count | 38 |
Formal Charge | 0 |
Complexity | 828 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Immune Checkpoint Inhibitors
Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. (See all compounds classified as Immune Checkpoint Inhibitors.)